ISELIN, N.J., Feb. 22, 2016 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a medical device company focused on non-invasive continuous glucose monitoring (CGM) and associated technologies, today announced new patents covering its system and methods for non-invasive, transdermal sensing as key components of Echo's continuous glucose monitoring system.
Echo Therapeutics received notice that its patent application entitled "System and Method for Analyte Sampling and Analysis with Hydrogel" issued as Canadian Patent No. 2,584,699 and will expire in 2025. Echo also recently received notice that its patent application entitled "Transdermal Analyte Monitoring Systems and Methods for Analyte Detection" was issued as Hong Kong Patent No. HK1143052 and will expire in 2028. Additionally, a notice of allowance was received for Japanese patent application 2013-250328, entitled "Sensor Assembly for an Analyte Monitoring System with Hydrogels and a Method for Monitoring an Analyte by Using the Sensor Assembly." These patents join an already extensive U.S. and foreign intellectual property portfolio.
"The issuance of these foundational patents creates an opportunity for Echo to establish strategic partnerships in these important regions of the world," said Scott W. Hollander, Echo's President and CEO. "Furthermore, we expect several additional patents to be filed and issued worldwide for our next generation skin preparation and continuous glucose sensing technology as we build a solid foundation for future and sustainable growth."
About Echo Therapeutics
Echo Therapeutics is developing its non-invasive, wireless, continuous glucose monitoring (CGM) system. A significant opportunity exists for the Company's CGM to be used in the outpatient diabetes market and in the fitness, weight loss and personal lifestyle wearable-health space. A longer-term opportunity also exists in the hospital settings. Echo developed its needle-free skin preparation device as a platform technology that allows for enhanced skin permeation enabling extraction of analytes, such as glucose, and enhanced delivery of topical pharmaceuticals.
Cautionary Statement Regarding Forward Looking Statements
The statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to regulatory approvals and the success of Echo's clinical studies, the safety and efficacy of Echo's CGM System, the failure of future development and preliminary marketing efforts related to Echo's CGM System, Echo's ability to secure additional commercial partnering arrangements, risks and uncertainties relating to Echo's and its partners' ability to develop, market and sell Echo's CGM System, the availability of substantial additional equity or debt capital to support its research, development and product commercialization activities, and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to its CGM System. These and other risks and uncertainties are identified and described in more detail in Echo's filings with the Securities and Exchange Commission, including, without limitation, its Annual Report on Form 10-K for the year ended December 31, 2014, its Quarterly Reports on Form 10-Q, and its Current Reports on Form 8-K. Echo undertakes no obligation to publicly update or revise any forward-looking statements.
For More Information: Christine H. Olimpio Director, Investor Relations and Corporate Communications (732) 201-4189
SOURCE Echo Therapeutics, Inc.